Skip to main content

Table 3 Examinations performed after suspected incidental malignancies on [18F]FDG-PET/CT in women with confirmed and not confirmed findings (n = 46)

From: Benefits and harms of implementing [18F]FDG-PET/CT for diagnosing recurrent breast cancer: a prospective clinical study

Suspected other malignancies*

Confirmed other malignancies

n

Not confirmed other malignancies

n

 

9 (4.00%)

 

37 (16.4%)

Sites of suspected lesions

 Thyroid cancer

1

Colon or upper gastrointestinal

15

 Lung cancer

1

Thyroid

11

 Skin cancer

1

Head and neck

4

 New breast cancer

1

Uro-gynecological

2

 Peritoneal cancer

1

Lung

2

 Kidney cancer

1

Mesenteric lymph node

1

 Malignant melanoma

1

Muscle (abdominal wall)

1

 Hematological cancer

1

Breast

1

  

Kidney

1

Clinical consequences

 Biopsy¤

8

Clinical examinations

16

 General anesthesia

7

Ultrasound

16

 Other surgery

4

Endoscopy (colon or ventricular)

14

 Follow-up CT or [18F]FDG- PET/CT

4

Biopsy¤

12

 Blood tests

4

Follow-up ultrasound

9

 Hospital admission

3

Laryngoscopy or cystoscopy

4

 Clinical examinations

3

Follow-up CT or [18F]FDG-PET/CT

4

 Medical treatment

3

General anesthesia

3

 Thyroidectomy

2

Hospital admission

3

 Ultrasound

2

Other surgery

2

 Bone marrow examination

1

Blood tests

2

 Cryoablation

1

MRI

1

 Renography

1

Endobronchial ultra sound

1

 Laryngoscopy

1

Thyroidectomy

1

 

CT urography

1

Gynecological examination

1

Severe complications

1

  1. *Ten patients suspected of incidental malignant findings were also suspected of MBC
  2. One patient had two additional incidental malignant findings
  3. ¤Including fine-needle aspiration in suspected lesions in the thyroid gland